期刊文献+

合并术前肌无力危象的重症肌无力临床特点和外科治疗 被引量:1

下载PDF
导出
摘要 目的:探讨合并术前肌无力危象的重症肌无力临床特点和外科治疗。方法:分析18例合并术前肌无力危象的重症肌无力临床特点和外科治疗经验,并以同期手术的176例无术前肌无力危象患者为对照组进行比较。结果:两组患者手术前Osserm an分期的构成比结构有明显差异(P=0.000);与对照组比较,术前危象组术后发生肌无力危象的风险增加(OR=4.451),术前危象组发生危象后机械通气时间明显延长(P=0.018);术前危象组的各项呼吸肌强度相关肺功能指标均有明显下降。结论:术前合并肌无力危象的重症肌无力见于全身型患者,手术后再发危象风险增加,手术前积极控制症状,调整机体状态可以部分改善预后;手术后机械通气时间适当延长,严格掌握拔管指征。
出处 《西南国防医药》 CAS 2009年第2期203-205,共3页 Medical Journal of National Defending Forces in Southwest China
  • 相关文献

参考文献15

  • 1鲁建军,马俊,罗红鹤,巫国勇,钟佛添.重症肌无力合并胸腺瘤手术治疗的近期疗效及危象发生的临床分析[J].中华胸心血管外科杂志,2007,23(4):237-239. 被引量:10
  • 2KIRMANI J F,YAHIA A M,QURESHI A I. Myasthenic crisis[J]. Curr Treat Options Neurol,2004,6( 1 ) :3 - 15.
  • 3王晓芳,丛志强,张本恕,周红梅.重症肌无力患者的死因分析[J].脑与神经疾病杂志,2007,15(1):55-56. 被引量:3
  • 4THOMAS C E,MAYER S A,GUNGOR Y,et al. Myasthenic crisis: clinical features, mortality, complicatios, and risk factors for prolonged intubation [ J ]. Neurology, 1997,48 (5) : 1253 - 1260.
  • 5JUEL V C. Myasthenia gravis:management of myasthenic crisis and perioperative care[ J]. Semin Neurol,2004,24( 1 ) :75 - 81.
  • 6O'RIORDAN J I, MILLER D H, MOTTERSHEAD J P, et al. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit [ J ]. Eur J Neurol, 1998,5(2) :137 - 142.
  • 7JARETZKI A, PENN A S, YOUNGER D S, et al. "Maximal" thy - mectomy for myasthenia gravis results[J]. J Thorac Cardiovasc Surg, 1988,95(5) :747 - 757.
  • 8SOLEIMANI A, MOAYYEPd A, AKHONDZADEH S, et al. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis :a 17 - year experience[J]. BMC Neurol ,2004 ,4 :12.
  • 9王旭广,杨鲲鹏,寿化山,丁旭青,郭亮.重症肌无力胸腺切除术后发生肌无力危象的危险因素[J].中华胸心血管外科杂志,2006,22(4):268-269. 被引量:15
  • 10MINCEWICZ G, ALOSZKO A, NYKA W, et al. The comparison of selected spirometric parameters with functional muscles exercise evaluation in patients with myasthenia [ J ]. Pol Merkur Lekarski, 2007,22(129) :177 - 181.

二级参考文献42

  • 1柳阳春,章晔,谢爱民,涂寒剑.“J”型胸骨上段切口胸腺切除治疗重症肌无力20例报告[J].江西医药,2005,40(1):10-11. 被引量:8
  • 2刘吉福.颈胸倒“L”形小切口治疗颈胸结合区肿瘤临床分析[J].中华医学杂志,2006,86(8):570-571. 被引量:5
  • 3王旭广,杨鲲鹏,寿化山,丁旭青,郭亮.重症肌无力胸腺切除术后发生肌无力危象的危险因素[J].中华胸心血管外科杂志,2006,22(4):268-269. 被引量:15
  • 4王维治,罗祖明.神经病学,第4版北京:人民卫生出版社,2002 283-288.
  • 5Evoli A. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand, 1988, 77(1): 31-35.
  • 6Diez Tejedor E. Evaluation of respiratory muscle function (maximal respiratory pressure) in myasthenia gravis. Neurologia, 1990, 5(9): 310-314.
  • 7Lecky BRF. Intercostal muscle acetylcholine receptors in longstanding ocular myasthenia. Lancet, 1980, 2(8207): 1311-1312.
  • 8Bolton CF. AAEM Minimongraph 40: clinical neurophysiology of the respiratory system. Muscle Nerve, 1993, 16(8): 809-818.
  • 9Bulkley GB,Bass,KN,Stephenson GR,et al.Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.Ann Surg,1997,226:324-335.
  • 10Kas J,Kiss D,Simon V,et al.Decade-long experience with surgical therapy of myasthenia gravis:early complications of 324 transsternal thymectomy.Ann Thorac Surg,2001,72:1691-1697.

共引文献43

同被引文献23

  • 1李亚红,王黎明,田丁军,张艳,陈锟,王晓燕,吕文红.自体干细胞移植治疗重症肌无力一例报告[J].中华神经科杂志,2005,38(4):219-219. 被引量:7
  • 2陈眉,周郁鸿,张宾辉,沈一平,侯群,叶宝东,张伟骏.自体外周血干细胞移植抢救重症肌无力危象一例[J].中华神经科杂志,2006,39(3):214-214. 被引量:4
  • 3肖毅,刘文励.自体造血干细胞移植治疗重症肌无力[J].中国医师进修杂志(内科版),2007,30(3):71-73. 被引量:2
  • 4Dinarello CA. Interleukine 1 and Interleukine 18 as mediators of inflammation and aging process [ J ]. Am J Clin Nutri, 2006, 83 (2) : 447.
  • 5Mea J, Paine M, Byme E, et al. Immunotherapy of ocular myas- thenia gravis reduce conversion to generalized myasthenia gravis [J]. J Neuroopnthalmol, 2003, 23(4): 251-255.
  • 6Benatar M, Kaminski HJ. Evidence report.. The medical treatment of ocular myasthenia (an evidence bassed review) [ J]. Neurology, 2007, 68(24): 2144-2149.
  • 7Juel VC, Massey JM. Myasthenia gravis [J]. Orphanet J Rare Dis, 2007, 2 : 44.
  • 8Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis [J]. Ann NY Acad Sci, 2008, 1132: 305-314.
  • 9Lavrnic D, Vujic A,Rakocevic-Stojanovic V, et al. Cyclosporine in the treatment of myasthenia gravis [J]. Acta Neurol Scand, 2005, 111(4) : 247.
  • 10Lim AK, Donnan G, Chambers B, et al. Myeophenolate mofetil substitution for cyclosporine-dependen! myasthenia gravis and nephrotoxicity [J]. Intern Med J, 2007, 37(1): 55-59.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部